Trial Profile
A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2022
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary) ; Dexamethasone; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PomdeSAR
- Sponsors Sanofi
- 14 Dec 2021 Results (n=34) presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 18 Jan 2021 Planned End Date changed from 1 Jun 2021 to 1 Mar 2021.